Literature DB >> 2493618

Natural history vs. surgery for Menière's disease.

H Silverstein1, E Smouha, R Jones.   

Abstract

Menière's disease has an episodic course, and certain patients undergo spontaneous remission of their vertigo. A retrospective study of patients treated from 1974 to 1983 was undertaken to evaluate the long-term outcome of patients with Menière's disease for whom surgery was recommended, comparing those who had a surgical procedure with a similar group of patients who declined surgery. The surgical procedures performed were endolymphatic subarachnoid shunt (ELS), retrolabyrinthine vestibular neurectomy (RVN), middle fossa vestibular neurectomy (MFVN), and transmeatal cochleo-vestibular neurectomy (CVN). We used a questionnaire, made up according to the 1985 American Academy of Otolaryngology (AAO) criteria, for reporting results for Menière's disease treatment, and compared patients who were offered surgery but declined (N = 50) with those who underwent surgery (N = 83). The data were analyzed statistically. Initial evaluation, which included air and bone conduction audiometry, speech discrimination, electronystagmography (ENG), frequency of vertigo attacks per month, and disability, showed both groups to be comparable at the outset. Of the non-operated group 57% had complete control of vertigo at 2 years; 71% had complete control after an average of 8.3 years. After an ELS, 40% of patients had complete control of vertigo after 2 years; 70% had complete control after an average of 8.7 years. After a neurectomy (RVN or CVN), 93% had complete control of vertigo (average followup, 4.4 years). These results indicate statistically that the ELS procedure does not alter the long-term natural course of vertigo control in Menière's disease, whereas both the RVN and CVN significantly improve the patient's chance of being permanently free of vertigo attacks.

Entities:  

Mesh:

Year:  1989        PMID: 2493618     DOI: 10.1177/019459988910000102

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  23 in total

Review 1.  Betahistine for Menière's disease or syndrome.

Authors:  A L James; M J Burton
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Meniere's Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

3.  [Transtympanic administration of gentamicin in Menière diseases--less is more!?].

Authors:  A Koitschev
Journal:  HNO       Date:  2003-11       Impact factor: 1.284

Review 4.  Menière's disease.

Authors:  Tony Wright
Journal:  BMJ Clin Evid       Date:  2015-11-05

5.  Vestibular results after intratympanic gentamicin therapy in disabling Menière's disease.

Authors:  Philippe Junet; Alexandre Karkas; Georges Dumas; Jean Louis Quesada; Sébastien Schmerber
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-16       Impact factor: 2.503

Review 6.  Menière's disease.

Authors:  Adrian L James; Marc A Thorp
Journal:  BMJ Clin Evid       Date:  2007-03-01

Review 7.  Ménière's disease.

Authors:  S N Merchant; S D Rauch; J B Nadol
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

8.  Patient Perceptions of Effectiveness in Treatments for Menière's Disease: a National Survey in Italy.

Authors:  Bryan Ward; Vincent Wettstein; John Golding; Giulia Corallo; Daniele Nuti; Franco Trabalzini; Marco Mandala
Journal:  J Int Adv Otol       Date:  2019-04       Impact factor: 1.017

9.  Endolymphatic sac surgery versus tenotomy of the stapedius and tensor tympani muscles in the management of patients with unilateral definite Meniere's disease.

Authors:  Silviu Albu; Gregorio Babighian; Maurizio Amadori; Franco Trabalzini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-07       Impact factor: 2.503

10.  Endolymphatic duct blockage: quality of life assessment of a novel surgical technique for Ménière disease.

Authors:  Nathalie Gabra; Marc-Henri Asmar; Djamal Berbiche; Issam Saliba
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.